Swiss - Delayed Quote CHF

Newron Pharmaceuticals S.p.A. (NWRN.SW)

7.28 +0.59 (+8.82%)
At close: 5:31 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NWRN.SW

Recent News: NWRN.SW

View More
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Business Wire 18 days ago
Newron Presents 2023 Financial Results and Provides 2024 Outlook

Newron Presents 2023 Financial Results and Provides 2024 Outlook
Business Wire last month
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Business Wire last month
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)
Business Wire 3 months ago
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide

Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
Business Wire 3 months ago
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria

Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria
Business Wire 6 months ago
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress

Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress
Business Wire 6 months ago
Newron Appoints Margarita Chavez as Board Advisor

Newron Appoints Margarita Chavez as Board Advisor
Business Wire 6 months ago
Newron Announces H1 2023 Results and Provides R&D Update

Newron Announces H1 2023 Results and Provides R&D Update
Business Wire 8 months ago
Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Business Wire 11 months ago
Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Business Wire 11 months ago
Newron Announces Senior Management Team Changes

Newron Announces Senior Management Team Changes
Business Wire 11 months ago
View More

Related Tickers

ADXN.SW Addex Therapeutics Ltd
0.1155
+0.43%
 
SPEX.SW Spexis AG
0.0590
+0.34%
 
SANN.SW Santhera Pharmaceuticals Holding AG
9.50
0.00%
 
XLS.SW Xlife Sciences AG
34.30
0.00%
 
IDIA.SW Idorsia Ltd
1.9000
+9.07%
 
RLF.SW Relief Therapeutics Holding SA
1.3000
+4.00%
 
12X1.F Anavex Life Sciences Corp.
3.0450
-0.23%
 
RVU.WA Ryvu Therapeutics S.A.
49.30
-1.00%
 
CTX.WA Captor Therapeutics Spolka Akcyjna
79.80
-0.25%
 
ADXN Addex Therapeutics Ltd
16.30
+5.78%